Navigation Links
Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
Date:11/17/2009

CAMBRIDGE, Mass., Nov. 17 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today additional preliminary results from an ongoing Phase 1 study of its lead development candidate, XMT-1001, in patients with advanced solid tumors. The results were presented in a poster session at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in Boston, MA November 15-19, 2009. XMT-1001 is a conjugate of the broad-spectrum cytotoxic camptothecin (CPT) that employs Mersana's Fleximer® platform.

XMT-1001 has continued to demonstrate promising tumor activity and favorable pharmacokinetic and tolerability profiles in the Phase 1 trial. Forty nine patients with refractory solid tumors have received 149 cycles of XMT-1001 at dose levels ranging from 1.0-85 mg CPT equivalents/m2. Twelve of 46 evaluable patients with advanced, refractory tumors demonstrated evidence of at least six weeks of stable disease. Nine of the 12 patients had prolonged stable disease for at least 12 weeks, including two patients for nine months. In addition, pharmacokinetic data for XMT-1001 have demonstrated dose proportional increases in exposure to the drug and confirms the formation of its release products according to the compound's design. The side-effect profile of XMT-1001 has been predictable and no toxicities associated with non-Fleximer-linked CPT or irinotecan, such as hemorrhagic cystitis or severe diarrhea, have been observed. The maximum tolerated dose (MTD) has not been reached and the Phase 1 study continues to accrue patients.

"We are very pleased to see that the data in this ongoing Phase 1 study for XMT-1001 continues to support our goal of establishing proof of concept fo
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
... 4, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... North America beyond physician offices and outpatient clinics with the ... and reference laboratories. The new line is expected to be ... regulatory approval and other requirements. Roche Diagnostics ...
... CLEMENTE, Calif., Oct. 4, 2011 ReShape Medical®, Inc. ... and chief executive officer.  Interim CEO, Ken Charhut, will ... chairman of the board for ReShape Medical.   ... and CEO of Luminous Medical, Inc., an innovative glucose ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2ReShape Medical Names Richard Thompson President and Chief Executive Officer 2
(Date:11/27/2014)... November 27, 2014 Absolute PhysioCare ... recently announced that its personalized treatment plans, highly ... can help victims of sports injuries reach pre-injury ... or patellofemoral pain syndrome, Absolute Physio has the ... jumper’s knee, ACL tears, meniscal injuries, groin strain ...
(Date:11/27/2014)... November 27, 2014 Cambrionix Ltd today announced ... Fast 50, a ranking of the 50 fastest-growing technology companies ... growth over the last five years. Cambrionix Ltd grew ... ranked first in the region of Cambridgeshire and East and ... Director Says:, “This award is recognition of the hard work ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... 2014 (HealthDay News) -- Thanksgiving meals can pose a ... diet, an expert says. Many traditional Thanksgiving dishes ... sauce -- are gluten-free, but "when it comes to ... be considered," Dr. Anca Safta, director of the Gluten ... Medical Center in North Carolina, said in a center ...
Breaking Medicine News(10 mins):Health News:Coquitlam Physiotherapy Clinic Now Helps Clients Reach Pre-Injury State 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... to prescription painkillers are more likely to succeed ... medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard ... the Archives of General Psychiatry. ... for Prescription Opioid Dependence," is the first large-scale ...
... A microsurgical procedure that has lost some ground ... role in the management of selected neurovascular disorders, according ... performs the procedure. "Though its indications are ... make all the difference for certain patients who have ...
... , MONDAY, Nov. 7 (HealthDay News) -- ... school athletes, a new study indicates. In neuromuscular ... progresses to focusing on muscles and motions used in ... and almost 1,500 female basketball and soccer players from ...
... by 2007 annual sales of the cards were at 85,000. America ... in the U.S. over the age of 80 is expected to ... how well they live. The new book, Aging Our Way ... of 30 eldersranging in age from 85 to 102living at home ...
... Go Fish with 3,000 cards. Scientists at Rochester Institute ... game with higher stakes. Instead of cards, they are matching ... body. Their research could lead to drugs that target proteins ... diseases. The three-year study is funded by a $417,000 ...
... who believe a rule or restriction is absolute are more likely ... wiggle room, according to a new study. The findings may ... Arab Spring uprisings, according to the authors of the study to ... Science . In the study, participants read articles that ...
Cached Medicine News:Health News:Suboxone is most effective in treating painkiller addiction 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 3Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:What can we learn from America's fastest growing and least understood age group? 2Health News:Opening the data bank -- scientists try to match new protein structures 2Health News:People Seem More Likely to Follow Rules They Can't Beat 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Thumb Spica Splint provides effective long-term ... custom fit. Adjustable radial and palmar ... for Gamekeper's thumb, de Quervain's, scaphoid ... closure straps.,FormFit™ Splints offer superior fit ...
Qualcare™ Thumb Spica...
... QuickCast® Cast-like splints Slip on, ... and QuickCast conforms to fit. ... Reheat to adjust and reposition. ... with a temperature-sensitive polymer Straps ...
Medicine Products: